Published in Breast Cancer Res Treat on September 22, 2010
Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One (2012) 3.74
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst (2014) 2.28
The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med (2013) 2.18
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol (2013) 1.92
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev (2013) 1.82
Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov (2012) 1.61
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res (2011) 1.48
Clinical relevance and biology of circulating tumor cells. Breast Cancer Res (2011) 1.34
Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol (2013) 1.33
Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res (2012) 1.21
Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer (2011) 1.19
Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med (2014) 1.18
Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther (2013) 1.15
Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. BMC Cancer (2013) 1.06
Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol (2015) 1.02
Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res (2014) 1.01
Gene signatures of breast cancer progression and metastasis. Breast Cancer Res (2011) 0.99
Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer. Breast Cancer Res (2013) 0.99
Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients. Proteome Sci (2011) 0.98
The promise of circulating tumor cell analysis in cancer management. Genome Biol (2014) 0.95
The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells. J Cancer Res Clin Oncol (2014) 0.94
Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Br J Cancer (2013) 0.94
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. Breast Cancer Res (2011) 0.93
Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? Cancers (Basel) (2014) 0.92
Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients. Biomed Res Int (2014) 0.90
Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticity. Front Oncol (2015) 0.90
Minimal residual disease and circulating tumor cells in breast cancer. Breast Cancer Res (2011) 0.87
Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients. Clin Transl Oncol (2015) 0.86
Clinical utility of circulating tumor cell counting through CellSearch(®): the dilemma of a concept suspended in Limbo. Onco Targets Ther (2014) 0.86
International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res (2014) 0.86
Breast Cancer Update 2014 - Focus on the Patient and the Tumour. Geburtshilfe Frauenheilkd (2015) 0.85
Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. Cancer Med (2013) 0.84
Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. BMC Cancer (2014) 0.84
Isolated, disseminated and circulating tumour cells in prostate cancer. Nat Rev Urol (2012) 0.84
Progress in using circulating tumor cell information to improve metastatic breast cancer therapy. J Oncol (2013) 0.84
Circulating tumour cells in breast cancer. Ecancermedicalscience (2013) 0.84
Circulating Tumor Cells: What Is in It for the Patient? A Vision towards the Future. Cancers (Basel) (2014) 0.84
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res (2015) 0.83
A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation. J Transl Med (2015) 0.83
Change of HER2 status in metastatic esophageal adenocarcinoma: heterogeneity of the disease? Case report and review of literature. J Gastrointest Oncol (2012) 0.82
Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat (2014) 0.82
Frequency of HER2 expression of circulating tumour cells in patients with metastatic or recurrent gastrointestinal cancer. Br J Cancer (2013) 0.82
Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients. Transl Oncol (2012) 0.81
'Omic approaches to preventing or managing metastatic breast cancer. Breast Cancer Res (2011) 0.81
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer (2015) 0.80
Single-cell analyses of circulating tumor cells. Cancer Biol Med (2015) 0.80
Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Breast Cancer Res (2015) 0.80
Sensitive and Specific Biomimetic Lipid Coated Microfluidics to Isolate Viable Circulating Tumor Cells and Microemboli for Cancer Detection. PLoS One (2016) 0.80
Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. J Cancer (2016) 0.80
EGFR and HER2 signaling in breast cancer brain metastasis. Front Biosci (Elite Ed) (2016) 0.79
May CTC technologies promote better cancer management? EPMA J (2015) 0.79
Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay. Int J Clin Oncol (2015) 0.79
Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. Geburtshilfe Frauenheilkd (2015) 0.78
An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients. BMC Cancer (2016) 0.78
Breast Cancer Biomarkers: Utility in Clinical Practice. Curr Breast Cancer Rep (2013) 0.78
Potential Role of Circulating Tumor Cell Detection and Monitoring in Breast Cancer: A Review of Current Evidence. Front Oncol (2016) 0.78
Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients. Cancer Res Treat (2015) 0.77
Disseminated and circulating tumor cells in bone marrow and blood of breast cancer patients: properties, enrichment, and potential targets. J Cancer Res Clin Oncol (2016) 0.77
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. Int J Cancer (2015) 0.77
Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer. Geburtshilfe Frauenheilkd (2015) 0.77
Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. Clin Exp Metastasis (2016) 0.77
Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. Neoplasia (2016) 0.76
Adaptation of semiautomated circulating tumor cell (CTC) assays for clinical and preclinical research applications. J Vis Exp (2014) 0.76
Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget (2016) 0.75
Single-cell sequencing and tumorigenesis: improved understanding of tumor evolution and metastasis. Clin Transl Med (2017) 0.75
Characterization of DNA Methylation in Circulating Tumor Cells. Genes (Basel) (2015) 0.75
Dissecting the Heterogeneity of Circulating Tumor Cells in Metastatic Breast Cancer: Going Far Beyond the Needle in the Haystack. Int J Mol Sci (2016) 0.75
Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry. Oncotarget (2017) 0.75
Androgen receptor expression on circulating tumor cells in metastatic breast cancer. PLoS One (2017) 0.75
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med (2009) 7.53
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res (2007) 6.59
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2010) 5.01
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med (2015) 4.97
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol (2013) 4.28
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11
Circulating tumor cells: liquid biopsy of cancer. Clin Chem (2012) 3.87
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol (2013) 3.87
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res (2009) 3.76
Cancer micrometastases. Nat Rev Clin Oncol (2009) 3.69
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst (2013) 3.46
Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res (2008) 3.32
Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2013) 3.29
Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology (2012) 3.28
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immunol (2009) 3.13
Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med (2010) 3.09
Magnetic resonance perfusion measurements for the noninvasive detection of coronary artery disease. Circulation (2003) 3.04
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res (2010) 2.98
A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14. Nat Med (2006) 2.85
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer (2005) 2.74
Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer (2008) 2.72
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
Circulating epithelial cells in patients with benign colon diseases. Clin Chem (2011) 2.57
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res (2013) 2.50
Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. Nat Med (2007) 2.41
Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol (2012) 2.38
Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res (2006) 2.36
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
A syndrome with congenital neutropenia and mutations in G6PC3. N Engl J Med (2009) 2.30
A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol (2013) 2.26
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Assessment of diffuse myocardial fibrosis in rats using small-animal Look-Locker inversion recovery T1 mapping. Circ Cardiovasc Imaging (2011) 2.21
Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery. Circulation (2004) 2.20
Circulating tumor cells and circulating tumor DNA. Annu Rev Med (2011) 2.16
p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis. J Cell Biol (2006) 2.15
Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res (2005) 2.10
Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell (2013) 2.08
OpenMM 4: A Reusable, Extensible, Hardware Independent Library for High Performance Molecular Simulation. J Chem Theory Comput (2012) 2.07
Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res (2008) 2.06
Risks associated with delivering infants 2 to 6 weeks before term--a review of recent data. Dtsch Arztebl Int (2012) 2.04
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol (2013) 2.02
Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med (2014) 2.00
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
Neonatal and maternal risk in Hermansky-Pudlak syndrome: peripartum management-brief report and review of literature. Arch Gynecol Obstet (2013) 1.98
Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol (2007) 1.84
The phenotype of human STK4 deficiency. Blood (2012) 1.84
A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer (2005) 1.83
A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res (2012) 1.83
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer (2006) 1.82
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev (2013) 1.82
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res (2012) 1.79
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol (2013) 1.79
Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol (2010) 1.79
Cancer micrometastasis and tumour dormancy. APMIS (2008) 1.78
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res (2009) 1.78
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res (2007) 1.78